? BIOINFORMATICS SHARED RESOURCE (BISR) The BISR is an essential shared resource that supports a wide range of studies with bioinformatics and computational biology needs, ranging from next generation sequencing (NGS) to data management in population science studies. Housed within the Department of BMI, the BISR's goal is to leverage a variety of informatics services, ranging from analysis of omics datasets to patient/participant-centered data instrumentation, access, and management tools and processes.
The Specific Aims of the BSR are to: 1) Provide state of the art bioinformatics and computational biology services; and 2) Provide OSUCCC investigators with services, expertise and access to technology platforms in support of heterogeneous and multi-dimensional biomedical data management requirements. Over the current grant cycle, Drs. Kevin Coombes (TT) and Lang Li (CB) assumed leadership of BISR, replacing Drs. Philip Payne and Jeffrey Parvin. During the current funding cycle, a Memorandum of Understanding (MOU) was established for the Department of Biomedical Informatics (BMI) and the OSUCCC to support 5 faculty at 10% per year for 3 years within BISR as they transition to grant funding, on a rolling basis, to provide non-chargeable, cancer focused bioinformatics work for OSUCCC membership and/or cancer focused researchers. Additional major changes for BISR include supporting the enhancement of the Genomics Shared Resource (GSR) to incorporate newly developed shared services with Nationwide Children's Hospital (NCH); and added capabilities to support studies involving data from single-cell sequencing, long-read (third generation) sequencing, metabolomics, and metagenomics. BISR has added five new faculty to support the areas of (1) computational optimization for drug sensitivity prediction (Cheng), (2) proteomics, and functional annotation of DNA non-coding regions (Zhang), (3) metabolomics and metagenomics (Mathe), (4) single-cell sequencing (Ma), and (5) long-read sequencing (Au). BISR supported Biospecimen Services Shared Resource (BSSR) projects (Total Cancer Care [TCC] and the Oncology Research Information Exchange Network [ORIEN]) by establishing a data warehouse of patient records with de-identified data. During the current funding cycle, the BISR supported 115 publications (25 > 10 impact factor), 134 users, and 32 NCI grants including 5 P01s, 2 P50s, 13 R01s, 3 R21s, 1 R50, 2 U01s, 1 U10, 1 UG1, involving members from all five programs. Over the next grant cycle, BISR will enhance services for ?integromics?, e.g., the integration of disparate source of both omics and clinical data. BISR will be a critical part of the Immune Monitoring and Discovery Platform (IMDP), an overarching approach for fostering interactions among shared resources for complex immuno-oncology projects. The annual budget of the BISR is $1,122,279, yet the CCSG request is $106,905. As such, the BISR leverages extensive institutional support and seeks only 9.5% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090004
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Volinia, Stefano; Bertagnolo, Valeria; Grassilli, Silvia et al. (2018) Levels of miR-126 and miR-218 are elevated in ductal carcinoma in situ (DCIS) and inhibit malignant potential of DCIS derived cells. Oncotarget 9:23543-23553

Showing the most recent 10 out of 2602 publications